WPO West Point Resources

West Point Resources Inc. (TSX VENTURE:WPO) (the "Company") is pleased to
announce it has entered into a binding letter of intent ("LOI") with Cannabix
Breathalyzer Inc. ("Cannabix") dated May 13, 2014, which is developing a cutting
edge marijuana breathalyzer for use by law enforcement to test for drug-impaired
drivers, in particular drivers who are impaired due to the use of marijuana. 


Cannabix's drug-impairment recognition system is based on breath testing
technology that has been developed in Sweden and has been clinically researched
and proven to be successful in testing individuals for recent consumption of the
THC component of marijuana. Cannabix is advancing its products to enable law
enforcement personnel to use this technology to enhance detection of marijuana
impaired driving offences on North American roads at a time when marijuana is
becoming legal in many jurisdictions. Cannabix holds patent applications on
leading edge technology to breath test for marijuana impairment. West Point will
be acquiring 100% of the exclusive North American licensing rights to Cannabix's
technology. 


Terms of the transaction 

The LOI contemplates the company paying 7.5 million common shares to Cannabix
for the exclusive licensing of the Cannabix Breathalyzer and issuing 7.5 million
warrants exercisable at $0.075, exercisable for one year. 


Financing 

The company intends to raise a minimum $500,000 via a non-brokered financing at
$0.05 cents per unit. Each Unit consists of one common share and one-half of one
non-transferable common share purchase warrant exercisable at $0.10 cents per
common share for a period of 12 months from the date of closing. All warrants
are subject to an early acceleration provision which provides for the mandatory
exercise or expiry of the Warrants in the event West Point's shares close at
$0.13 or higher for at least 10 consecutive trading days. In such event, the
Warrants will accelerate and expire 30 days after the Company has given notice
of the accelerated conversion to the Warrant holders. Finders' fees may be
payable in connection with the private placement in accordance with exchange
policies. 


As conditions of closing, along with minimum $500,000 financing required to be
raised, Cannabix will nominate two members to the Board of Directors of the
company. 


Additional milestone payments 

The LOI contemplates future share payments upon reaching the following
milestones: The issuance of 7,500,000 of common shares of West Point within 14
business days of production of prototype of product. Furthermore, upon receipt
of the final patent, the company will issue 5,000,000 common shares of West
Point.  


About Cannabix Breathalyzer Inc. 

Cannabix Breathalyzer Inc is privately held medical device company that has
developed a drug-testing device that can detect Tetrahydrocannabinol (THC- the
psychoactive component of marijuana that causes intoxication) using breath
samples. The science behind the breath-testing device is based on breath testing
technology developed at the Karolinska University in Sweden and perfected by the
founders of Cannabix Breathalyzer Inc. The device provides rapid detection of
THC and can be used roadside to identify drivers intoxicated by the use of
marijuana. The device can also be useful for other practical applications such
as testing employees in the workplace where intoxication by THC can be
hazardous. 


The founders and current shareholders of Cannabix Breathalyzer include: 

Mr. Kal Malhi: 

Mr. Malhi is a Vancouver-based entrepreneur and the founder of Cannabix
Breathalyzer Inc. Mr. Malhi is a retired member of the Royal Canadian Mounted
Police and is also President of BullRun Group, a private investment company
specializing in early stage business development. Mr Malhi brings a wealth of
business and law enforcement experience to the management team and is cognizant
of the issues of protecting individuals' rights to privacy while maximizing
public safety through law enforcement initiatives. 


Dr. Raj Attariwala: 

Dr. Attariwala, MD, PhD, FRCPC, FANM is a Vancouver based dual board certified
Radiologist and Nuclear Medicine physician certified in both Canada and the
United States. He holds a doctorate in Biomedical Engineering from Northwestern
University (Evanston, IL). 


Dr. Attariwala has worked closely with the breath testing technology developed
by the Karolinska Institute and Dr. Olof Beck and utilized his educational
training and background in biomedical engineering to formulate product design
and patent applications for Cannabix Breathalyzer products. Dr. Attariwala also
has several other medical device patents under developments in the field of
nuclear medicine. 


Dr. Bruce Goldberger: 

Bruce A. Goldberger, PhD, DABFT, is the director of University of Florida Health
Forensic Medicine, a professor, and the director of toxicology for the
Department of Pathology, Immunology and Laboratory Medicine in the College of
Medicine at the University of Florida 


He also performs as the technical and administrative director of the University
of Florida Forensic Toxicology Laboratory, which provides toxicological services
to medical examiner offices and state and local law enforcement agencies
throughout the state. In his other roles, Dr. Goldberger is the editor-in-chief
of the Journal of Analytical Toxicology; the president of the American Board of
Forensic Toxicology; and was a past-president of the American Academy of
Forensic Sciences. 


Halt in trading 

The transaction will constitute an arm's length change of business ("COB" as
defined in the policies of the TSX Venture Exchange) of West Point. Upon
completion of the transaction, it is expected that the company will be
classified as a technology company. 


Trading of West Point shares on the TSX Venture will remain halted until the
transaction is completed. The company intends to delist from the TSX Venture
Exchange and apply for a listing on the Canadian Securities Exchange (the CSE).
Completion of the transaction is subject to a number of conditions, including
shareholder approval, among other conditions. The transaction cannot close until
the required shareholder approval is obtained. There can be no assurance that
the transaction will be completed as proposed or at all.


Investors are cautioned that, except as disclosed in the Management Information
Circular and/or Filing Statement to be prepared in connection with the
transaction, any information released or received with respect to the COB may
not be accurate or complete and should not be relied upon. Trading in the
securities of West Point should be considered highly speculative. 


The TSX Venture Exchange has in no way passed upon the merits of the proposed
transaction and has neither approved nor disapproved the contents of this press
release.


We seek Safe Harbor. 

On behalf of the Board of Directors

Rav Mlait, President and CEO 

West Point Resources Inc. 

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT
TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.


FOR FURTHER INFORMATION PLEASE CONTACT: 
West Point Resources Inc.
(604) 551-7831
604-676-2767 (FAX)
info@westpointresources.com
www.westpointresources.com

West Point Resources (TSXV:WPO)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

West Point Resources (TSXV:WPO)
Historical Stock Chart
Von Jun 2023 bis Jun 2024